About

President

Hui Zhou, PhD, is responsible for the product development of new drugs in the oncology pipeline, including medical strategy, clinical pharmacology, clinical operations, medical affairs and oncology product line layout and management. Dr. Zhou received his MD from Fudan University. He joined Innovent in 2016 and has led the clinical development of multiple oncology studies including that of Sintilimab.

Dr. Zhou has served as a member of several academic organizations, including the Clinical Research Professional Committee of the Chinese Anti-Cancer Association. Before joining the pharmaceutical industry, he was a doctor at Fudan University’s Zhongshan Hospital. Prior to joining Innovent, Dr. Zhou worked in the medical and R&D departments at AstraZeneca, Amgen and Roche.

Head of Regulatory Affairs

Raj Dhodda, PhD, is responsible for the Company’s Global regulatory affairs and the development of regulatory strategies, interacts and negotiates evidence with FDA, EMA and other global regulatory authorities across all therapeutic areas. Dr. Dhodda received her integrated PhD in Molecular Biochemistry from University of Madras, India, and University of Wisconsin-Madison and completed a postdoctoral degree at University of Wisconsin-Madison, USA. She has earned a second advanced Masters certificate in Regulatory Affairs – Oncology at San Diego State University, USA.

Dr. Dhodda’s career includes regulatory leadership roles with increasing responsibilities at Abbvie, Takeda, Sumitomo Pharma Oncology (Sunovion), Covance, and PPD. She has led teams as a key regulatory expert and an adaptive strategist over her 23 years and has a track record of developing and implementing successful global regulatory strategies leading to NDA, BLA approvals in multiple therapeutic areas.

Dr. Dhodda is a well-recognized leader and a standing mentor and chair at the Healthcare Businesswoman’s Association Midwest chapter.

William Liu, MD, serves as Vice President, Head of Clinical Operations, leading the Global Clinical Operations team in Oncology. He plays a pivotal role in developing and executing the global product development strategy, overseeing the planning and implementation of clinical trials, and ensuring compliance with regulatory requirements.

Dr. Liu is responsible for enhancing cross-functional collaborations, driving operational efficiency, and fostering strategic partnerships to advance oncology research and development. He joined Fortvita in January 2024, bringing his expertise to lead strategic initiatives and operational excellence in oncology clinical operations.

Dr. Liu has 18 years of Global Clinical Operations experience both in MNC and biotech. Before joining Fortvita, he worked at Bayer with variety increasing responsibilities in Global Oncology Clinical Development Operations and ABM Therapeutics as Head of Clinical Operations.

General Counsel

Fred Medick, JD. General Counsel. Fred oversees legal support for Fortvita. He holds a Juris Doctor from Harvard Law School cum laude and a B.A. from Stanford University. He joined Fortvita in 2025, bringing more than 15 years of experience in healthcare law, FDA regulatory practice, compliance, contracting, and litigation. Before joining Fortvita, he served as Assistant General Counsel at Genentech and Senior Counsel at Amgen. Earlier in his career, he served as a federal prosecutor at the U.S. Department of Justice, investigating life sciences companies and evaluating corporate compliance programs. He clerked on the U.S. District Court and Fifth Circuit Court of Appeals.

Head of IT & Data Sciences

Michael Zhang, PhD, is responsible for building up the IT and system infrastructure to streamline operations and R&D activities. Michael joined Fortvita in 2024, bringing more than 25 years of experience in Pharmaceutical R&D, clinical, quality & compliance systems, data science & IT. Before joining Fortvita, he served as VP of IT & Data Sciences at Brii Biosciences and Sr. Director of Development Operations Systems at Gilead. He received his PhD in Chemistry from University of Houston and B.S. in Chemistry from Beijing University.

Head of Fortvita US Office

Leah is an experienced Research Scientist with over 25 years in biotech, currently serving as Head of Fortvita’s US Office. Specializing in oncology research, she excels in cell biology and analytical techniques.

Before joining Fortvita, Leah progressed from UCSF to Exelixis and spent over two decades at Gilead Sciences, advancing from Senior Research Associate to Research Scientist. As US Office Head, Leah manages critical operational responsibilities including strategic partnership development, research team leadership, and regulatory compliance oversight.